# Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT04546620** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital Southampton NHS Foundation Trust** · enrollment: 453 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** R-CHOP
- **DRUG:** R-CHOP + acalabrutinib

## Key facts

- **NCT ID:** NCT04546620
- **Lead sponsor:** University Hospital Southampton NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-19
- **Primary completion:** 2027-11
- **Final completion:** 2028-05
- **Target enrollment:** 453 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04546620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04546620, "Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04546620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*